MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke
January 7, 2026 | Intelligent Commercialization
The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.
How AI and LLMs are shaping audience intelligence in life sciences
In the episode, they examine how life sciences companies are approaching AI and Large Language Models (LLMs), the challenges created by gaps in data sets, and why context and real behavior matter when predicting how healthcare professionals and patients engage.
Why real behavior and high-quality data are critical for predictive accuracy
The discussion focuses on several key themes, including:
- The limitations of narrow or closed data inputs and how they restrict prediction accuracy
- The importance of understanding real behavior beyond a single organization’s data
- Why high-quality, holistic data sets are essential to improving LLM performance
- The role of subject matter experts in providing context that general-purpose models currently lack
- How data quality directly influences the usefulness and reliability of AI tools
Together, Jamie and Iris highlight how more precise, behavior-informed audience intelligence can support better decision-making as AI becomes increasingly central to life sciences marketing and engagement.
Listen to the full MM+M Podcast episode: “Beyond the algorithm: What AI-powered audience intelligence really means in 2026.”
Intelligent Commercialization™ in action
This perspective is core to how Inizio delivers Intelligent Commercialization™ – our unified, expert-driven approach that connects proprietary data, technology, and AI to unlock measurable impact across the product lifecycle. Platforms such as Cognitev™ and Predictev™ (referenced in the discussion) translate over 35M hours of real-world behavior into actionable intelligence, enabling clients to anticipate shifts, optimize engagement, and make smarter decisions with confidence.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on…
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at…
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only…
Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Pegasus expands Pharma team with senior hires
Five new recruits support further growth of the Pharma & Life Sciences team
Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we’ve been using facial analysis to delve further into respondents’ reactions…
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU & Japan) 2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in…
News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1…
Emerging Markets: Your Essential Guide
Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges…
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,…